Effect of Apelin on Insulin Sensitivity in Type 2 Diabetic Volunteers
Status:
Completed
Trial end date:
2017-04-01
Target enrollment:
Participant gender:
Summary
Preclinical studies have demonstrated in mouse models that (PYR1)-apelin-13 exerts a
glucose-regulating action in vivo. The (PYR1)-apelin-13 effect on insulin sensitivity in
healthy overweighed volunteers has been previously assessed in a phase I clinical trial
(APELINS study; NCT02033473). The APELINS-2 clinical trial aims to expand the initial proof
of concept to the population targeted by future innovative insulin-sensitizing therapies:
patients living with type 2 diabetes.